An announcement from KalVista Pharmaceuticals ( (KALV) ) is now available.
On April 8, 2025, KalVista Pharmaceuticals entered into a License, Supply, and Distribution Agreement with Kaken Pharmaceutical for the commercialization of sebetralstat in Japan. This agreement includes an upfront payment of $11 million and potential milestone payments up to $24 million, plus royalties. Sebetralstat, if approved, would be the first oral on-demand treatment for HAE in Japan, marking a significant commercial opportunity for both companies.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
KalVista Pharmaceuticals scores a 52.2, reflecting a blend of financial challenges and positive strategic moves. Significant weaknesses in financial performance and valuation are counterbalanced by strong technical momentum and promising corporate developments. Key risks include the company’s ongoing financial struggles, while the strategic appointment and technical indicators offer potential upside.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing oral therapies for rare diseases with unmet needs. Its lead investigational product, sebetralstat, is an oral, on-demand treatment for hereditary angioedema (HAE) currently under regulatory review in multiple regions.
YTD Price Performance: 29.80%
Average Trading Volume: 517,767
Technical Sentiment Signal: Hold
Current Market Cap: $532.5M
For an in-depth examination of KALV stock, go to TipRanks’ Stock Analysis page.